Current Treatment Options for nAMD
Significance of SRF vs IRF in nAMD
Experts discuss the management of subretinal fluid (SRF) and intraretinal fluid (IRF) in patients with neovascular age-related macular degeneration (nAMD).
Markers of Disease Progression in nAMD Patients
Veeral Sheth, MD, MBA, FASRS, FACS, offers clinical advice on marking disease progression in neovascular age-related macular degeneration (nAMD).
Treat and Extend Strategy for Anti-VEGF Injections
Experts offer their clinical experience and advice for applying a treat and extend strategy with anti-vascular endothelial growth factor (Anti-VEGF) injections.
Real-World Long-Term Safety Data of Anti-VEGF Agents
Experts discuss safety data of anti-vascular endothelial growth factor (Anti-VEGF) agents while highlighting the importance of sharing this information with patients and relevant care providers.
Patient and Cross-Care Education Strategies for AMD and DME
Experts discuss strategies for educating patients, fellows, and shared-care providers on therapies and prospective outcomes for patients with age-related macular degeneration (AMD) or diabetic macular edema (DME).
Barriers to Optimal Treatment Outcomes
Experts discuss barriers that prevent optimal outcomes for patients with age-related macular degeneration (AMD) or diabetic macular edema (DME).
Overview of Anti-VEGF Treatments for AMD and DME
Experts provide an overview of anti-vascular endothelial growth factor (Anti-VEGF) treatment for patients with age-related macular degeneration (AMD) or diabetic macular edema (DME).
The Future of Treatment for Diabetic Macular Edema
Dr Theodore Leng discusses what the future may hold for patients with diabetic macular edema.
Emerging Treatment Options for Diabetic Macular Edema
Dr. Ehsan Rahimy describes the emerging treatment options for diabetic macular edema.
Diabetic Macular Edema: Faricimab
Joseph M. Coney, MD, provides an overview of the drug faricimab for treating diabetic macular edema.
Anti-VEGF Agents and Diabetic Retinopathy Severity Score
Retina specialists review clinical trial data on the impact of anti-VEGF agents on diabetic retinopathy severity scores.
Maintenance Treatment for Diabetic Macular Edema
Key opinion leaders describe maintenance treatments for diabetic macular edema and provide an overview of the PANORAMA study.
Considerations for Switching Diabetic Macular Edema Treatments
Ehsan Rahimy, MD, and Theodore Leng, MD, FACS, discuss how to assess patient response to treatment and when to switch agents.
Reviewing Anti-VEGF Agents in Clinical Practice
Dr Joseph M. Coney reviews his personal experience using anti-VEGF agents to treat diabetic macular edema in his clinical practice.
Diabetic Macular Edema: Limitations of Anti-VEGF Agents
Retina experts discuss the limitations of anti-VEGF agents in treating diabetic macular edema.
Anti-VEGF Agents for Diabetic Macular Edema
Theodore Leng, MD, FACS, describes the currently available anti-VEGF agents for treating diabetic macular edema and what factors to consider when choosing a therapy.
Treatment Options for Diabetic Macular Edema
Ehsan Rahimy, MD, and Joseph M. Coney, MD, review the available treatment options for diabetic macular edema.
Diabetic Macular Edema with Concomitant Conditions
A professor of ophthalmology describes how concomitant conditions with diabetic macular edema affect the urgency of treatment regimens.
Progression of Diabetic Macular Edema
A panel of experts explains how diabetic macular edema progresses over time and how to educate patients about progression prevention.
Diagnostic Testing for Diabetic Macular Edema
Dr Theodore Leng reviews the preferred testing options for diabetic macular edema.
Pathophysiology of Diabetic Macular Edema
Retina specialists describe how diabetic retinopathy leads to diabetic macular edema, and the pathophysiology of the condition.
An Overview of Diabetic Macular Edema
Joseph M. Coney, MD, and Theodore Leng, MD, FACS, define diabetic macular edema and explain the typical symptoms to watch for and patient referral patterns.
Initiating Conversations with Patients about Anti-VEGF Agents
Key opinion leaders emphasize important considerations when discussing the safety of anti-VEGF agents with patients and highlight unmet needs in nonproliferative diabetic retinopathy treatments.
Updates in the Management of Non-Proliferative Diabetic Retinopathy
Drs Ehsan Rahimy and Joseph M. Coney analyze the implications of clinical trial data on the management of nonproliferative diabetic retinopathy.
A Review of Clinical Trial Data in Non-Proliferative Diabetic Retinopathy
A panel of experts reviews data on nonproliferative diabetic retinopathy treatments from the PANORAMA, Protocol W, RISE, and RIDE studies.
Non-Proliferative Diabetic Retinopathy: Goals of Therapy
Dr Joseph M. Coney provides insight into the goals of therapy for patients with nonproliferative diabetic retinopathy.
Early Detection of Non-Proliferative Diabetic Retinopathy
Joseph M. Coney, MD, and Ehsan Rahimy, MD, explain the complications of nonproliferative diabetic retinopathy and emphasize the importance of early detection.
An Overview of Diabetic Retinopathy
Drs Ehsan Rahimy and Diana V. Do define diabetic retinopathy and describe the symptoms.
Making Informed Therapy Decisions for Macular Edema
Expert ophthalmologists debate the rationale behind choosing an anti-VEGF inhibitor for patients and the challenges involved in treatment management.
2 Clarke Drive Cranbury, NJ 08512